Clinical Indications and Safety Considerations for Capsule Endoscopy

Primary Clinical Indications

The American Gastroenterological Association recommends that capsule endoscopy (CE) should be performed in patients with overt gastrointestinal bleeding and negative findings on both esophagogastroduodenoscopy (EGD) and colonoscopy, ideally within 48 hours of the bleeding episode, to maximize diagnostic and therapeutic yield 1, 2
The European Society of Gastrointestinal Endoscopy suggests that CE is the first-line examination for suspected small-bowel bleeding given its excellent safety profile, patient tolerability, and ability to visualize the entire small-bowel mucosa, with a diagnostic yield of 49.3% 1, 2
The American College of Gastroenterology recommends CE as the first-line examination in patients with iron-deficiency anemia when small bowel evaluation is indicated, particularly in selected patients with unexplained, mild, chronic iron-deficiency anemia 1, 2

The Crohn's and Colitis Foundation suggests that CE should be performed in patients with suspected, known, or relapsed Crohn's disease when ileocolonoscopy and imaging studies are negative, if it is imperative to know whether active Crohn's disease is present in the small bowel, with CE having greater sensitivity for mucosal small-bowel Crohn's disease than radiological imaging techniques 1, 2, 3
The European Crohn’s and Colitis Organisation recommends that CE should be used as the initial diagnostic modality for investigating the small bowel in the absence of obstructive symptoms or known bowel stenosis, with a critical caveat that CE should be restricted to patients with high clinical suspicion and who have abstained from NSAID ingestion for at least 1 month 4, 6

The American Society for Gastrointestinal Endoscopy warns that the most significant complication of CE is capsule retention, which occurs when the capsule becomes lodged in the small bowel, usually at stricturing disease sites, with a risk of retention in suspected Crohn's disease of 3.6% and in established Crohn's disease of 8.2% 4, 6
The society recommends that when obstructive symptoms are present or in known stricturing Crohn's disease, a patency capsule should precede CE, and patients with history of small bowel resection, abdominal/pelvic radiation exposure, or chronic NSAID use should also have patency capsule assessment 4, 6

The European Society of Gastrointestinal Endoscopy suggests that in patients with suspected Crohn's disease, fecal calprotectin should be checked, NSAID abstinence should be ensured for ≥1 month, and assessment for obstructive symptoms should be performed before proceeding to CE 4, 6
The society recommends that in patients with iron-deficiency anemia, CE should only be performed if there is a high suspicion for small bowel source, and that patients must be counseled about potential risks including failed procedure, capsule retention, and missed lesions 1, 2